News @ at a glance

The article offers world news briefs related to health. A campaign to allow research institutions and pharmaceutical companies to register the 20 core elements of their clinical trials involving human beings has been launched by the World Health Organization (WHO). The "Journal of the American Medical Association" plans to tighten its financial conflict-of-interest policy beginning in January 2007. According to WHO, up to 60,000 people die annually from malignant melanomas and other forms of skin cancer.

ACCESSION #

22469918

Related Articles

The article comments on the efforts to create a comprehensive registration for clinical trials. Current discussions center on negotiations with the pharmaceutical and medical devices industries about the information to be registered for which trials and when it should be done. An international ...

The article focuses on the proposal of the World Health Organization (WHO) concerning the publication of plans for all clinical trials by pharmaceutical companies on the Internet that include early-stage proof-of-concept studies. WHO requires all medical studies that test treatments on human...

The article presents a report on a system for tracking global clinical trials. The World Health Organization (WHO) hopes to earn international support next week for a far-reaching plan to set up a global tracking system for clinical trials. These measures are intended to reduce the duplication...

An interview with Sir Iain Chalmers, library editor of the James Lind Library is presented. When asked about the importance of clinical trials and how does the James Lind Library fit in, he relates that clinical trial assess whether claims about the effects of treatments are dangerous or...

Reports that the World Health Organization will unveil the first global clinical trials register in November 2004. Criticisms on drug companies that suppressed vital data; Potential of the register to establish international procedures; Plans of the WHO to use an existing numbering system.

The article reports that patients with advanced melanoma who participated in early tests of an experimental drug seemed to show signs of a slowdown in the spreading of the deadly skin cancer. According to Synta Pharmaceuticals Corp., test patients who received the drug survived an average of 3.7...

Focuses on the challenges facing health, nutrition and population global programs in relation to the specific needs of each country. Indication that global programs are not effectively linked with country assistance; Potential for conflicts of interest in in-house program Secretariats.